For example, cell lines with PTEN loss or PIK3CA mutations have been shown to be significantly more sensitive to the Akt inhibitors in a variety of tumor types, while cells lines with RAS mutations are generally resistant even in the presence of concomitant PIK3CA mutations [42–44, 50]. Here, PTEN is linked to neoplasm.